<div id="readability-page-1"><div>Overview<ul><li>HeartBeam Q3 net loss widens to $5.3 mln, with increased R&amp;D expenses, vs loss of $5 mln year ago</li><li>Company anticipates FDA clearance for 12-lead ECG software by year-end</li><li>HeartBeam partners with HeartNexus for on-demand cardiologist reviews</li></ul>Outlook<ul><li>HeartBeam anticipates FDA clearance for ECG software by Q4 2025</li><li>Company plans to initiate commercialization post-FDA clearance</li></ul>Key Details<div><table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q3 EPS</td><td></td><td>-$0.15</td><td></td></tr><tr><td>Q3 Net Income</td><td></td><td>-$5.26 mln</td><td></td></tr><tr><td>Q3 Basic EPS</td><td></td><td>-$0.15</td><td></td></tr><tr><td>Q3 Income From Operations</td><td></td><td>-$5.29 mln</td><td></td></tr><tr><td>Q3 Operating Expenses</td><td></td><td>$5.29 mln</td><td></td></tr></tbody></table></div>Analyst Coverage<ul><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 2 &#34;strong buy&#34; or &#34;buy&#34;, 1 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell&#34;</li><li>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is &#34;buy&#34;</li><li>Wall Street's median 12-month price target for Heartbeam Inc is $4.00, about 58.3% above its November 12 closing price of $1.67</li></ul>Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</div></div>

BEAT

HeartBeam's Q3 net loss widened to $5.3 million due to increased R&D expenses, compared to a $5 million loss a year ago. The company expects FDA clearance for its 12-lead ECG software by year-end and plans to commercialize post-clearance. Analyst ratings are mostly 'buy' with a median 12-month price target of $4.00, 58.3% above the current price.

Heart monitor maker HeartBeam Q3 net loss widens on increased R&D expenses